There are a variety of different mutations that can underlie hereditary retinal dystrophy. Thanks to the development of modern molecular genetic testing methods, the genetic cause can nowadays be identified in the majority of cases. An innovative gene therapy is available for patients with retinal dystrophy due to biallelic RPE65 mutations.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Chronic wounds
State-of-the-art wound management: pioneering innovations
- Allergic rhinitis
International consensus paper summarizes important facts
- Obesity
Possibilities of nutritional therapy
- Headache treatment
The therapy of migraine
- Uveal melanoma
Development of a CAR T-cell therapy for uveal melanoma
- Electrolyte disturbance
Hyponatremia in the outpatient setting
- Study report: Risk factors for hand eczema
Population-based data provides valuable new insights
- SGLT2i for heart failure